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Abstract
Background: Pressure ulcers are a major problem, especially in nursing home patients, although they are regarded as
preventable and there are many pressure relieving methods and materials. One such pressure relieving material is the recently
developed Australian Medical Sheepskin, which has been shown in two randomized controlled trials [1,2] to be an effective
intervention in the prevention of sacral pressure ulcers in hospital patients. However, the use of sheepskins has been debated
and in general discouraged by most pressure ulcer working groups and pressure ulcer guidelines, but these debates were based
on old forms of sheepskins. Furthermore, nothing is yet known about the (cost-)effectiveness of the Australian Medical
sheepskin in nursing home patients.
The objective of this study is to assess the effects and costs of the use of the Australian Medical Sheepskin combined with usual
care with regard to the prevention of sacral pressure ulcers in somatic nursing home patients, versus usual care only.
Methods/Design: In a multi-centre randomised controlled trial 750 patients admitted for a primarily somatic reason to one of
the five participating nursing homes, and not having pressure ulcers on the sacrum at admission, will be randomized to either
usual care only or usual care plus the use of the Australian Medical Sheepskin as an overlay on the mattress.
Outcome measures are: incidence of sacral pressure ulcers in the first month after admission; sacrum pressure ulcer free days;
costs; patient comfort; and ease of use. The skin of all the patients will be observed once a day from admission on for 30 days.
Patient characteristics and pressure risk scores are assessed at admission and at day 30 after it.
Additional to the empirical phase, systematic reviews will be performed in order to obtain data for economic weighting and
modelling.
The protocol is registered in the Controlled Trial Register as ISRCTN17553857.
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Background
"How to prevent or heal pressure sores is an ever-present prob-
lem for nurses, and they have had many and varied ideas for
solving it. Some of their methods have been helpful; others have
been failures. Sometimes old methods that were not 100 per
cent effective have been put aside for new ones, and, occasion-
ally, an old one is revived to be tried again. Such a method is
sheepskin therapy (Woodruff, 1952) [3]."
This historical quote is interesting, since it shows that
pressure ulcers have been a major problem for many
years. Furthermore it is interesting because it states that
old therapies sometimes are revived, such as the sheep-
skin. More than 50 years later the sheepskin, now labelled
as the 'Australian Medical Sheepskin', has its second
revival.
Pressure ulcers are highly prevalent, especially among eld-
erly residing in nursing homes, where about 30% of the
patients are suffering from these sores [4-7]; a Canadian
study in two nursing homes even found a prevalence rate
up to 53% [8]. A USA-study in 12 nursing homes found a
mean incidence rate of 13.6%, varying between 3 and
31% [9]. Incidence rates for Dutch nursing homes are
scarce: one study found an incidence rate of 25% in the
first four weeks after admission [10]. Pressure ulcers are
not just a very common problem, they also represent a
major burden and reduce quality of life for patients and
their carers; pressure ulcers cause prolonged contact with
the health care system, pain, discomfort and inconven-
ience [11-15].
Pressure ulcers are considered as a problem that to a large
extent can be prevented by good care; therefore the inci-
dence and prevalence rates are now put forward by many
health care, professional and governmental organizations
as an indicator of the quality of health care [16-20].
The prevention and therapy of pressure ulcers are very
costly [13,21-25]. However, economic evaluations of
pressure-relieving devices for the prevention of pressure
ulcers are few and far between [26].
Pressure ulcers develop when capillary circulation is
obstructed by prolonged pressure. Also shear and friction
are contributing factors for the development of pressure
ulcers. Therefore many interventions are in use to mini-
mize pressure on bony prominences, such as reposition-
ing and different kinds of pressure relieving devices
[23,27,28]. Sheepskin is one such pressure relieving
device. According to a literature review of the Australian
Commonwealth Scientific and Industrial Research Organ-
ization (CSIRO) [29], it is known that sheepskins have
pressure relieving properties, as was already demonstrated
in studies dating back to the 1930s, 1950s and 1960s.
Besides this, sheepskins have good moisture absorbing
capacities. Therefore sheepskins have long been in use to
prevent pressure ulcers. However, the old natural sheep-
skins could not retain their pressure reducing capacities
after frequent washings; hygienic problems also arose
because they could not withstand washing above 40
degrees. Later many attempts were made to produce artifi-
cial sheepskins, but none had the same pressure reducing
or moisture absorbing properties. And so the use of sheep-
skins, both genuine and artificial, was almost completely
discontinued and came to be regarded as ineffective [30].
Currently none of the guidelines known to us on pressure
ulcer prevention and treatment mention or encourage the
application of any form of sheepskin. However, in the
1990s, interest in genuine sheepskin was renewed. March-
and et al.[31] found promising results, which prompted
the Australian Commonwealth Scientific and Industrial
Research Organization, CSIRO, to develop new methods
for producing new genuine medical sheepskins with very
high pressure reducing capacities but without the disad-
vantages of the old sheepskins. The Australian Medical
Sheepskin is a real genuine sheepskin, coming from the
Australian Merino sheep. The sheepskin has a wool pile
length of 30 mm, and a high density of wool piles. The
sheepskin is tanned and processed in such a way that it
has an increased resistance to urine and can withstand up
to 60 washes at 80°C to achieve high-level thermal disin-
fection, without losing its moisture absorbing and pres-
sure relieving properties.
This new Australian Medical Sheepskin has been tested
extensively on pressure relieving characteristics, laundry
procedures, disinfection, wear-and-tear, patient comfort
and other aspects [32]. The necessary qualities for a sheep-
skin to be called an Australian Medical Sheepskin are
described in the National Australian Standard AS 4480.1
[33]. The effectiveness of the Australian Medical Sheep-
skin in the prevention of pressure ulcers was first tested
clinically in a randomized controlled trial in 297 elderly
orthopedic hospitalized patients with very good results:
incidence rate of pressure ulcers was 9.6% in the interven-
tion versus 30% in the control group [1]. These results
were confirmed in another randomized trial with 441
adults patients from different hospital wards [2]. Both
studies were well designed, with the latter awarded for the
best research article published in the Medical Journal of
Australia of 2004. The application of Australian Medical
Sheepskins is very easy for nursing and care personnel and
for patients [1,2]. These trial results led to positive com-
ments and recommendations in three recent systematic
reviews [27,28,34].
However, the question arises as to whether these results in
acute hospital patients can be replicated in the more
chronic and vulnerable nursing home patients, who areBMC Health Services Research 2008, 8:4 http://www.biomedcentral.com/1472-6963/8/4
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generally at higher risk for developing pressure ulcers. In
addition, in the Australian studies the cost-effectiveness
was not assessed.
We therefore consider it is worthwhile to study the effects
in nursing home patients and to assess the cost-effective-
ness of the Australian Medical Sheepskin.
Methods/Design
Research aims and questions
The purpose of this study is to assess the costs and effects
of the Australian Medical Sheepskin combined with usual
care in the prevention of sacral pressure ulcers in nursing
home patients, versus usual care only.
Research questions are:
1. What are the effects of the application of Australian
Medical Sheepskins on the incidence rates of sacral pres-
sure ulcers in somatic nursing home patients in the first
month after admission compared to usual care?
2. What are the costs of the application of the Australian
Medical Sheepskin?
3. What are the costs of the treatment for eventually devel-
oped pressure ulcers in the two study groups?
4. What is the cost-effectiveness of the Australian Medical
Sheepskin compared to usual care?
5. What adverse effects do Australian Medical Sheepskins
have?
6. How do patients and nursing and care personnel rate
the (dis)comfort of Australian Medical Sheepskins and
the ease of use of Australian Medical Sheepskins?
Design
The proposed study concerns a prospective multi-centre
randomised controlled trial with one experimental and
one control group. The starting point is a superiority
design with the research hypothesis that Australian Medi-
cal Sheepskins are a better pressure relieving device than
usual care; that they will reduce the incidence rates of sac-
ral pressure ulcers; and will also reduce costs involving
pressure ulcer treatment.
Data will be gathered primarily in an empirical way and
additionally through systematic literature searches with
regard to the cost-effectiveness question.
For assessing the cost-effectiveness, the Australian Medical
Sheepskin will be compared only to usual care and not to
other pressure relieving materials. The perspective of the
health care organisation will be considered to measure the
cost-effectiveness.
Participants
The study population will concern patients newly admit-
ted for a primarily somatic condition to one of the five
participating nursing homes. Only patients who are free
of sacral pressure ulcers on admission will be included.
Further inclusion criteria are: adult; not having darkly pig-
mented skin (because of difficulty in diagnosing grade 1
pressure ulcer); having an expected stay of more than one
week; and consenting to the research.
For practical reasons and because 74% of nursing home
patients in the Netherlands are at risk for pressure ulcer
development [4], we have chosen to involve all patients,
and not only patients at risk.
The patients will be recruited from 5 different Dutch nurs-
ing home care groups (Amstelring, Florence, Frankeland,
Sutfene, Swinhove) involving seven different geographi-
cal locations and 18 wards. The selection of the nursing
homes was made on the basis of the customer list of the
laundry company that we contacted, and which is able to
do the washing and drying of the sheepskin, according to
the Australian Standard [35].
Inclusion of patients started on May 1st 2007 and will pro-
ceed until the targeted number of patients is reached, for
a maximum of 1.5 years. It is expected that enough
patients will be admitted during this period to reach the
necessary number as was calculated by power-analysis.
Sample size calculation
In Dutch nursing homes the prevalence of pressure ulcers
is about 30% for all grades and about 12% for grade 2 to
4 [4]. Few studies have investigated incidence rates for
Dutch nursing homes: one study found an incidence rate
of 25% in the first four weeks after admission [10]. The
first studies [1,2] on the Australian Medical Sheepskin
found incidence rates of 30% in the control group and
9.6% for the intervention group.
For this study we will consider the Australian Medical
Sheepskin to be effective and clinically significant if the
incidence rate in the first month after admission is at least
(in absolute terms) 10 percentage points lower in the
experimental group than in the control group. This means
that with an expected maximum incidence rate of 18% in
the experimental group and about 28% in the control
group, 750 patients (2 × 375) are needed to find such dif-
ferences with a power of at least 80% and a two-sided
alpha of 0.05.BMC Health Services Research 2008, 8:4 http://www.biomedcentral.com/1472-6963/8/4
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Halfens et al.[4] state that 68% of the pressure ulcers in
nursing homes originate during the nursing home stay;
accordingly, with a prevalence of 30%, this means that
approximately 10% of the patients are admitted with an
already existing pressure ulcer, and will therefore not ful-
fill our inclusion criteria. Furthermore, it is expected that
about 10% of the patients will refuse to participate and
that about 5% will drop-out from the study for other rea-
sons (e.g. not being able to discuss matters and give
informed consent). Allowing for drop-out and for the fact
that not all patients are pressure ulcer free when admitted
to the nursing home, 1000 patients (2 × 500) will be
recruited. Based on the admission data of previous years,
it is assumed that about 1,350 patients will be admitted in
the planned 18 months of patient inclusion. The expected
patient inclusion flow is shown in Figure 1.
Patient allocation/randomisation sequence/blinding
All newly admitted patients will be checked by the nurse
in charge at admission to ascertain whether they fit the
inclusion criteria. If so, they will be given research infor-
mation in written format and verbally by the same nurse
at admission. On the next day they will be asked for
informed consent (by the same nurse) and if they agree,
the nurse will immediately call the central research office
to find out to which group the patient has been rand-
omized. Thus, the therapy according to randomization
status will start immediately and within less than 48 hours
after admission.
To ensure concealment of allocation, a randomization
scheme was created in SPSS by assigning the intervention
to a random sample of circa 50% in a list of 1,500 num-
bers and assigning the control group to the rest. This allo-
cation of the group (sheepskin, usual care) was then
blinded on a paper list numbered 1 through 1,500 by a
secretary not further involved in the project. Each time a
patient is admitted, the principal investigator located at
the central research office is called. The above list with
numbers and blinded allocation is held at this office. This
Flow chart expected patient inclusion Figure 1
Flow chart expected patient inclusion.BMC Health Services Research 2008, 8:4 http://www.biomedcentral.com/1472-6963/8/4
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central research office registers each patient identity for
every consecutive number and discloses the group alloca-
tion to the nurse and patient.
Only the patient allocation itself is blinded to all parties
involved, because it is impossible to blind health profes-
sionals or patients to whether someone is in the sheepskin
group or not.
Intervention
The experimental condition consists of the application of
the Australian Medical Sheepskin as an overlay on top of
the standard/usual mattress in the area of the buttocks
and in the (wheel)chair, combined with all care as usual.
An extra Australian Medical Sheepskin at the bottom of
the bed is also permitted. The intervention will start no
later than 48 hours after admission. The Australian Medi-
cal Sheepskin will be applied during the first 30 days after
admission (and prolonged if the patients wish so, but
without gathering research data). The period of 30 days is
chosen because most pressure ulcers develop in the first
weeks after admission [6,10,36,37]. The sheepskins will
be changed at least every two days.
Besides the use of the Australian Medical Sheepskin, all
other usual pressure ulcer preventative interventions such
as mobilization and repositioning may be added as co-
interventions, in so far as they are normally used in the
participating nursing homes. All other nursing care can be
continued as usual (including incontinence materials).
The control group will receive usual care, including all the
pressure relieving interventions and other preventive
actions, normally taken in the participating nursing
homes. The application, in any way, of the Australian
Medical Sheepskin is forbidden in this group.
Outcomes
A distinction can be made between variables relating to
the effectiveness (incidence, prevalence of pressure ulcers)
and variables relating to costs (purchase and washing of
the sheepskins on the one hand, and investment of time
and materials cost for pressure ulcer treatment on the
other). Both of these are necessary to compute cost-effec-
tiveness.
The primary outcomes for this study are:
- the incidence of sacral pressure ulcers in the first 30 days
after admissions,
- the costs of appliance of the sheepskin, and
- the costs related to treatment of the pressure ulcers that
have developed.
Secondary outcomes are the presence of pressure ulcers on
other places, quality of life, comfort of the sheepskin as
experienced by the patients and ease of use of the sheep-
skin as experienced by the care personnel.
Influencing factors that will be measured are patient char-
acteristics, the application of other pressure relieving
interventions and materials and the use of incontinence
materials.
Instruments
These outcomes, as well as influencing factors, will be
measured by appropriate instruments, as far as possible
we will use already existing and validated instruments.
The EPUAP grading system is used to assess the presence
and severity of pressure ulcers [38].
To this end a 'daily observation checklist' has been devel-
oped. Nurses use this checklist during the first 30 days
after admission to report the presence/absence of sacral
pressure ulcers, as well as the ulcer grade; the presence/
absence of pressure ulcers on other locations and whether
a sheepskin, repositioning, other support surfaces and
incontinence material are applied.
When nurses feel uncertain about their observations they
are instructed to call another specialized nurse, experi-
enced in observing pressure ulcers.
Furthermore, a photographic series of the various pressure
ulcer grades is available on each ward, as well as special
glasses that can be used in order to differentiate better
between blanchable and non-blanchable erythema.
Finally, all nursing homes are offered a lesson in pressure
ulcer observation.
The daily skin observations by nurses during routine care
will be checked weekly by an experienced nurse observa-
tor from the nursing home itself and bimonthly by the
principal investigator from the central research office.
Influencing patient factors that will be measured are age,
gender, principal medical diagnosis category, surgery in
the last month, presence of pressure ulcers at admission
on other places than the sacrum, incontinence status,
nutritional status (including body mass index), activity of
daily living level (Barthel-index) and pressure ulcer risk
score (Braden-scale). These are measured twice: at admis-
sion and at day 30 after it.
Furthermore the patients in the sheepskin group are asked
at the end of the research period to rate the (dis)comfort
of the sheepskin. For this purpose, a self-developed 7-item
questionnaire with a 5-point rating answer structure was
developed.BMC Health Services Research 2008, 8:4 http://www.biomedcentral.com/1472-6963/8/4
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Data about costs that will be gathered are the costs of buy-
ing sheepskins, costs of washing sheepskins, costs of treat-
ment of pressure ulcers (medication, wound care
materials, diagnostics, kind of specialized consultants and
time involved, and extra time for nurses/carers with regard
to pressure ulcer treatment).
For this purpose, invoices from the firms in question will
be used, or the best approximations as far as these are
available in Dutch (governmental) sites/organizations.
In summary, in order to register the above-mentioned
data, the following five forms were created: admission
form, daily observation form, end of research period
form, sheepskin comfort questionnaire and the pressure
ulcer therapy cost form (these forms in Dutch can be
obtained on request from the first author).
The initial assessment at admission is completed for all
patients that fulfill the inclusion criteria, in order to con-
duct a post hoc check as to whether there was selective
attrition in patients not willing to participate.
Ease of use of the sheepskin for carers will be measured by
group interviews to be held on three occasions during the
research period.
Data-analysis
First of all the primary outcomes will be analyzed using
descriptive methods.
Statistical testing of differences in incidence and preva-
lence between experimental and control groups will be
conducted by a two-sided Chi-square test. In addition, dif-
ferences in number of pressure ulcer free days will be
tested with a two-sided t-test for independent samples;
and differences in onset of pressure ulcers will be analyzed
with Kaplan Meier curves. All analyses will be controlled
for influencing factors. Moreover, a multi level analysis
will be performed because of the fact that data are gath-
ered from several organizations and nursing wards.
Both intention-to-treat-analysis and per-protocol-analysis
will be carried out.
The economic data about costs will be used in a model
approach to show the economic consequences on a
higher level. The aim is to develop a model that can show
the consequences of implementing improved pressure
ulcer care for an average nursing home and/or the
national level.
Ethical considerations
Patients will be informed verbally and in written format
about the research project before they are asked to partic-
ipate and before they sign the informed consent form,
which will also be signed by the nurse in charge at admis-
sion. At all times patients are free to stop their participa-
tion without having to give a reason for doing so.
The study protocol has been reviewed and approved by
the certified Medical Ethical Review Board of the Univer-
sity Medical Centre of Utrecht (protocol number 06/287),
on behalf of all the participating nursing homes.
The Board of directors of each participating nursing home
signed a form in which they state they have read and
understood the research protocol and that there are no
obstacles at all to perform the research in their organiza-
tions.
The scientific merits of the study protocol have been
reviewed in the consecutive phases of research funding
process by the independent reviewers of the funding
organization ZonMw, the Netherlands Organization for
Health Research and Development [39]. The ZonMw
grant obtained is number 945-07-513.
Next to this, the research protocol, and more specifically
the washing procedure of the sheepskins, has also been
judged by the Dutch Working Party on Infection Preven-
tion [40] and has been approved as safe.
Additional systematic reviews
In addition to the empirical data gathering, systematic lit-
erature reviews will be performed to retrieve adjuvant data
concerning:
- costs of pressure ulcer treatment,
- pressure ulcer incidence and duration per grade in nurs-
ing home patients, and
- influence of pressure ulcers on quality of life.
These reviews will be conducted in order to compare the
empirically found cost-effectiveness data to other studies,
and to improve economic modelling and scenarios.
For these systematic reviews a protocol has been written
including databases to be searched, search strategies,
inclusion criteria and process, methodological assessment
and data-analysis. These review protocols (in Dutch) can
be obtained from the authors.
Publication
All results from this study will be submitted to suitable
peer reviewed journals and will be presented at appropri-
ate international conferences.BMC Health Services Research 2008, 8:4 http://www.biomedcentral.com/1472-6963/8/4
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The patient inclusion process started on May 1st 2007 and
is expected to continue until the end of 2008. First results
are not expected earlier than mid-2009.
Funding
A grant (number 945-07-513) was obtained in a compet-
itive application process of the efficacy research program,
round 2007, of the Netherlands Organization for Health
Research and Development ZonMw [39].
Discussion
This study is innovative because it is the first to assess the
cost-effectiveness of the Australian Medical Sheepskin in
nursing home patients and also because current opinions
and guidelines [13,41-44] oppose the use of sheepskins.
However, these are based on old forms of sheepskins, not
comparable to the genuine Australian Medical Sheepskin.
A difficult point in this research is that the usual care can
not be standardized. Although nurses and nursing homes
may have pressure ulcer protocols and say that they are
following these, there is a chance that the usual care differs
from nursing home to nursing home, or even from nurs-
ing ward to nursing ward, and that individual nurses may
deviate from the protocol. Moreover, it is known that dif-
ferent mattresses are in use in and between nursing
homes. Since standardization is in no way possible, a reg-
istration of mattresses and devices applied will be con-
ducted.
With regard to possible contamination between experi-
mental and control group, the following measures will be
taken: clear instruction to all nursing and care personnel
and patients, a limited stock of sheepskin on the ward,
daily inspection of the skin by the research team in both
groups, and a concise control and observation to ascertain
whether the patients are still being nursed in the condi-
tion they were randomized to. Moreover it is not very
likely that patients from both groups will be nursed on the
same room during the same period (1.2 admissions per
bed); therefore it is improbable that patients from the
control group will ask for a sheepskin.
Finally, in the information sessions with nurses, it will be
stressed that the Australian Medical Sheepskin is NOT a
replacement for the normal pressure relieving interven-
tions such as repositioning and other methods.
With regard to treatment adherence, patients from the
intervention group are asked only to keep the sheepskin
in their bed for 30 days. No other action is required from
patients other than actions that are also asked in the con-
trol group. However it remains possible that some
patients after a few days will refuse the sheepskin (e.g.
because of itching, not feeling comfortable, too hot, or
other reason): in these cases the use of the Australian Med-
ical Sheepskin will be stopped without persuading
patients to continue, but they will be asked if the daily
skin observations can be continued. Records will be kept
of patients that have discontinued the use of the Austral-
ian Medical Sheepskin (including reasons to stop), and
they will be analyzed in the group they were randomized,
according to intention to treat analysis principles.
Conclusion
The Australian Medical Sheepskin is a new pressure reliev-
ing overlay, which has been proven to be effective to pre-
vent pressure ulcers in two randomized controlled trials
among hospital patients. However, it is not known yet if
the Australian Medical Sheepskin is also an effective pre-
vention for pressure ulcers in nursing home patients; nor
is it known what the cost-effectiveness characteristics are
of the Australian Medical Sheepskin are. This study will
attempt to answer these questions.
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